Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Intangibles CIM

Confidential Information Memorandum or CIM, a marketing document

CIM will highlight your company’s intangible assets and suggest how buyers can utilize them to grow, increase profits, or mitigate risk. Of course, buyers will do their own due diligence on your assets, and lots more, before closing the deal, so all assertions in the CIM must be reasonable. Overhyping a company can be a quick turnoff for buyers.

How Buyers can utilized LPBI Group’s IP Asset Classes I, II, III, V are described in

Opportunities Map in the Acquisition Arena

https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

Intangible assets are non-physical assets that provide value to a business, including items such as

LPBI Group’s trademarks

• No filing for Trademarks

LPBI Group’s copyrights

• All content on PharmaceuticalIntelligence.com is copyrighted under Creative Common law
• The sole owner and operator is LPBI Group’s Founder: Aviva Lev-Ari, PhD, RN

LPBI Group’s patents

• Our content is not Patentable

LPBI Group’s contracts

• Montero Language Services, Madrid, Spain
• Amazon.com, Kindle Direct Publishing
• WordPress.com
• LinkedIn.com

LPBI Group’s customer lists

• IP Address of 1,400,230 distinct e-Visitors to the Website generators of 2,215,966 views, All times on 3/14/2023
• All subscribers to the Website

LPBI Group’s proprietary software

Web stat compute at article level

• https://pharmaceuticalintelligence.com/sop-web-stat/

Work flow for using NLP for Medical Text Analysis

• https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

Blockchain architecture

• https://pharmaceuticalintelligence.com/blockchain-transactions-network/

Synthetic Biology Softward in Drug Discovery

• https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

Compute Projected Article Views

• https://pharmaceuticalintelligence.com/vision/pharmaceuticalintelligence-com-journal-projecting-the-annual-rate-of-article-views/

LPBI Group’s databases, designs

LPBI Group’s proprietary business processes

LPBI Group’s well protected trade secrets

LPBI Group’s works of authorship

LPBI Group’s key employees

1.0 & 2.0 LPBI Group’s Team

• Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0
• Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences
• Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
• Shraga Rottem M.D., D.Sc., Expert, Author, Writer & External Scientific Relations on AI in Medical Applications
• Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases

INACTIVE 12/31/2021

• Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery

INACTIVE 12/31/2022

• Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer, Marketing Communications

INACTIVE 12/31/2022

• Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML

Joel Shertok, PhD – Affiliation with LPBI Group: 12/22/2019 – 5/4/2021

• Joel Shertok, PhD, ex-Member of The Board, ex-Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group

Justin D. Pearlman – External Scientific Relations: starting 5/12/2021

• Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author

LPBI Group’s strategic relationships

• Montero Language Services, Madrid, Spain
• GTO, Madrid, Spain

LPBI Group’s audit reports

LPBI Group’s credentials

LPBI Group’s licenses

• No licenses in place

LPBI Group’s brand recognition

SOURCE

Highlight Your Company’s Intangible Assets When Selling

https://www.exitstrategiesgroup.com/blog/sell-a-business

Al Statz at 707-781-8580 or alstatz@exitstrategiesgroup.com